Updated:
ACELYRIN
ACELYRIN resolves to Alumis Inc., a biotech advancing targeted oral therapies for immune-mediated diseases with Phase 3 data reported in March 2026.
ACELYRIN
We are using a precision approach to develop therapies designed to transform the lives of patients with immune-mediated diseases.
General information
Firm type
Single Family Office
Year founded
—
AUM
Undisclosed
Location
Region
North America
Country
United States
City
Agoura Hills
Corporate office
Agoura Hills, CA, United States
Sector focus
Frequently asked questions
Does ACELYRIN operate as a family office or an asset manager?
ACELYRIN's website redirects to Alumis Inc., which presents itself as a biopharmaceutical company, not a family office or asset manager. No wealth-origin narrative, external capital allocation mandate, or multi-asset investment structure is disclosed on its site. The entity functions as an operating company developing drug therapies.
What is ACELYRIN/Alumis's lead drug candidate?
Envudeucitinib is the lead oral small-molecule candidate, targeting plaque psoriasis. Two Phase 3 trials reported data in March 2026 showing early and robust improvements in skin clearance, quality of life, and psoriasis symptoms. The company is positioning it as a potential leading oral therapy in the space.
What is the scope of ACELYRIN's pipeline?
The disclosed pipeline is concentrated on immune-mediated diseases. Alumis states it is advancing a late-stage portfolio of next-generation targeted therapies designed to optimize outcomes across a wide range of such conditions, supported by a proprietary data analytics platform.
Does ACELYRIN participate in fund commitments or only direct investments?
There is no evidence that ACELYRIN/Alumis participates in fund commitments. All disclosed activity relates to internal drug development operations. External GP commitments, co-investments, or fund-of-funds allocations are not mentioned in its corporate materials.
How is ACELYRIN related to Alumis?
The acelyrin.com domain redirects to Alumis Inc. Alumis operates as the public-facing clinical-stage biotech. No separate family office, parent entity, or spinout structure is described on the Alumis website.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: